Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous tianeptine for reversal of remifentanil-induced respiratory depression in healthy volunteers
NL-OMON24262Recruiting
- Sponsor
- AMO Pharma
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of tianeptine in opioid-induced respiratory depression (OIRD) (3 arms), sponsored by AMO Pharma. Primary endpoints: Tianeptine plasma concentrations and Minute ventilation. Started Jun 2019; status: recruiting.
02
Drugs
tianeptine
03
Conditions
opioid-induced respiratory depression (OIRD)
Beyond the preview
Go deeper on NL-OMON24262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24262.